2023-04-202024-04-302024-04-30false14817506RIAAR PHARMA LIMITED2025-01-1147730falseiso4217:GBPxbrli:pure148175062023-04-20148175062024-04-30148175062023-04-202024-04-30148175062023-04-19148175062023-04-19148175062023-04-192023-04-1914817506bus:SmallEntities2023-04-202024-04-3014817506bus:AuditExempt-NoAccountantsReport2023-04-202024-04-3014817506bus:AbridgedAccounts2023-04-202024-04-3014817506bus:PrivateLimitedCompanyLtd2023-04-202024-04-3014817506core:WithinOneYear2024-04-3014817506core:AfterOneYear2024-04-3014817506core:WithinOneYear2023-04-1914817506core:AfterOneYear2023-04-1914817506core:ShareCapital2024-04-3014817506core:SharePremium2024-04-3014817506core:RevaluationReserve2024-04-3014817506core:OtherReservesSubtotal2024-04-3014817506core:RetainedEarningsAccumulatedLosses2024-04-3014817506core:ShareCapital2023-04-1914817506core:SharePremium2023-04-1914817506core:RevaluationReserve2023-04-1914817506core:OtherReservesSubtotal2023-04-1914817506core:RetainedEarningsAccumulatedLosses2023-04-1914817506core:LandBuildings2024-04-3014817506core:PlantMachinery2024-04-3014817506core:Vehicles2024-04-3014817506core:FurnitureFittings2024-04-3014817506core:OfficeEquipment2024-04-3014817506core:NetGoodwill2024-04-3014817506core:IntangibleAssetsOtherThanGoodwill2024-04-3014817506core:ListedExchangeTraded2024-04-3014817506core:UnlistedNon-exchangeTraded2024-04-3014817506core:LandBuildings2023-04-1914817506core:PlantMachinery2023-04-1914817506core:Vehicles2023-04-1914817506core:FurnitureFittings2023-04-1914817506core:OfficeEquipment2023-04-1914817506core:NetGoodwill2023-04-1914817506core:IntangibleAssetsOtherThanGoodwill2023-04-1914817506core:ListedExchangeTraded2023-04-1914817506core:UnlistedNon-exchangeTraded2023-04-1914817506core:LandBuildings2023-04-202024-04-3014817506core:PlantMachinery2023-04-202024-04-3014817506core:Vehicles2023-04-202024-04-3014817506core:FurnitureFittings2023-04-202024-04-3014817506core:OfficeEquipment2023-04-202024-04-3014817506core:NetGoodwill2023-04-202024-04-3014817506core:IntangibleAssetsOtherThanGoodwill2023-04-202024-04-3014817506core:ListedExchangeTraded2023-04-202024-04-3014817506core:UnlistedNon-exchangeTraded2023-04-202024-04-3014817506core:MoreThanFiveYears2023-04-202024-04-3014817506core:Non-currentFinancialInstruments2024-04-3014817506core:Non-currentFinancialInstruments2023-04-1914817506dpl:CostSales2023-04-202024-04-3014817506dpl:DistributionCosts2023-04-202024-04-3014817506core:LandBuildings2023-04-202024-04-3014817506core:PlantMachinery2023-04-202024-04-3014817506core:Vehicles2023-04-202024-04-3014817506core:FurnitureFittings2023-04-202024-04-3014817506core:OfficeEquipment2023-04-202024-04-3014817506dpl:AdministrativeExpenses2023-04-202024-04-3014817506core:NetGoodwill2023-04-202024-04-3014817506core:IntangibleAssetsOtherThanGoodwill2023-04-202024-04-3014817506dpl:GroupUndertakings2023-04-202024-04-3014817506dpl:ParticipatingInterests2023-04-202024-04-3014817506dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-202024-04-3014817506core:ListedExchangeTraded2023-04-202024-04-3014817506dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-202024-04-3014817506core:UnlistedNon-exchangeTraded2023-04-202024-04-3014817506dpl:CostSales2023-04-192023-04-1914817506dpl:DistributionCosts2023-04-192023-04-1914817506core:LandBuildings2023-04-192023-04-1914817506core:PlantMachinery2023-04-192023-04-1914817506core:Vehicles2023-04-192023-04-1914817506core:FurnitureFittings2023-04-192023-04-1914817506core:OfficeEquipment2023-04-192023-04-1914817506dpl:AdministrativeExpenses2023-04-192023-04-1914817506core:NetGoodwill2023-04-192023-04-1914817506core:IntangibleAssetsOtherThanGoodwill2023-04-192023-04-1914817506dpl:GroupUndertakings2023-04-192023-04-1914817506dpl:ParticipatingInterests2023-04-192023-04-1914817506dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-192023-04-1914817506core:ListedExchangeTraded2023-04-192023-04-1914817506dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-192023-04-1914817506core:UnlistedNon-exchangeTraded2023-04-192023-04-1914817506core:NetGoodwill2024-04-3014817506core:IntangibleAssetsOtherThanGoodwill2024-04-3014817506core:LandBuildings2024-04-3014817506core:PlantMachinery2024-04-3014817506core:Vehicles2024-04-3014817506core:FurnitureFittings2024-04-3014817506core:OfficeEquipment2024-04-3014817506core:AfterOneYear2024-04-3014817506core:WithinOneYear2024-04-3014817506core:ListedExchangeTraded2024-04-3014817506core:UnlistedNon-exchangeTraded2024-04-3014817506core:ShareCapital2024-04-3014817506core:SharePremium2024-04-3014817506core:RevaluationReserve2024-04-3014817506core:OtherReservesSubtotal2024-04-3014817506core:RetainedEarningsAccumulatedLosses2024-04-3014817506core:NetGoodwill2023-04-1914817506core:IntangibleAssetsOtherThanGoodwill2023-04-1914817506core:LandBuildings2023-04-1914817506core:PlantMachinery2023-04-1914817506core:Vehicles2023-04-1914817506core:FurnitureFittings2023-04-1914817506core:OfficeEquipment2023-04-1914817506core:AfterOneYear2023-04-1914817506core:WithinOneYear2023-04-1914817506core:ListedExchangeTraded2023-04-1914817506core:UnlistedNon-exchangeTraded2023-04-1914817506core:ShareCapital2023-04-1914817506core:SharePremium2023-04-1914817506core:RevaluationReserve2023-04-1914817506core:OtherReservesSubtotal2023-04-1914817506core:RetainedEarningsAccumulatedLosses2023-04-1914817506core:NetGoodwill2023-04-1914817506core:IntangibleAssetsOtherThanGoodwill2023-04-1914817506core:LandBuildings2023-04-1914817506core:PlantMachinery2023-04-1914817506core:Vehicles2023-04-1914817506core:FurnitureFittings2023-04-1914817506core:OfficeEquipment2023-04-1914817506core:AfterOneYear2023-04-1914817506core:WithinOneYear2023-04-1914817506core:ListedExchangeTraded2023-04-1914817506core:UnlistedNon-exchangeTraded2023-04-1914817506core:ShareCapital2023-04-1914817506core:SharePremium2023-04-1914817506core:RevaluationReserve2023-04-1914817506core:OtherReservesSubtotal2023-04-1914817506core:RetainedEarningsAccumulatedLosses2023-04-1914817506core:AfterOneYear2023-04-202024-04-3014817506core:WithinOneYear2023-04-202024-04-3014817506core:Non-currentFinancialInstrumentscore:CostValuation2023-04-202024-04-3014817506core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-04-202024-04-3014817506core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-04-202024-04-3014817506core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-04-202024-04-3014817506core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-04-202024-04-3014817506core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-04-202024-04-3014817506core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-04-202024-04-3014817506core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-04-202024-04-3014817506core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-04-202024-04-3014817506core:Non-currentFinancialInstrumentscore:CostValuation2024-04-3014817506core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-04-3014817506core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-04-3014817506core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-04-3014817506core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-04-3014817506core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-04-3014817506core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-04-3014817506core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-04-3014817506core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-04-3014817506core:Non-currentFinancialInstrumentscore:CostValuation2023-04-1914817506core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-04-1914817506core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-04-1914817506core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-04-1914817506core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-04-1914817506core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-04-1914817506core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-04-1914817506core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-04-1914817506core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-04-1914817506bus:Director12023-04-202024-04-30

RIAAR PHARMA LIMITED

Registered Number
14817506
(England and Wales)

Unaudited Financial Statements for the Period ended
30 April 2024

RIAAR PHARMA LIMITED
Company Information
for the period from 20 April 2023 to 30 April 2024

Director

RIAAR, Jasdeep Singh

Registered Address

12 The Wharf 16 Bridge Street
Birmingham
B1 2JS

Registered Number

14817506 (England and Wales)
RIAAR PHARMA LIMITED
Balance Sheet as at
30 April 2024

Notes

2024

£

£

Fixed assets
Investments31,288,924
1,288,924
Current assets
Debtors46,287
Cash at bank and on hand11
6,298
Creditors amounts falling due within one year5(502,764)
Net current assets (liabilities)(496,466)
Total assets less current liabilities792,458
Creditors amounts falling due after one year6(792,358)
Net assets100
Capital and reserves
Called up share capital100
Shareholders' funds100
The financial statements were approved and authorised for issue by the Board of Directors on 11 January 2025, and are signed on its behalf by:
RIAAR, Jasdeep Singh
Director
Registered Company No. 14817506
RIAAR PHARMA LIMITED
Notes to the Financial Statements
for the period ended 30 April 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
2.Average number of employees

2024
Average number of employees during the year1
3.Fixed asset investments
Shares in group undertakings and participating interests £1,288,924 .

Total

£
Cost or valuation
Additions1,288,924
At 30 April 241,288,924
Net book value
At 30 April 241,288,924
At 19 April 23-
4.Debtors: amounts due within one year

2024

£
Amounts owed by group undertakings6,287
Total6,287
5.Creditors: amounts due within one year

2024

£
Bank borrowings and overdrafts32,160
Amounts owed to related parties133,886
Other creditors336,718
Total502,764
6.Creditors: amounts due after one year

2024

£
Bank borrowings and overdrafts792,358
Total792,358